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Calcification has limited the clinical utility of bioprosthetic heart valves fabricated from 
either glutaraldehyde-pretreated bovine pericardium or porcine aortic valves. Aminopro- 
panehydroxydiphosphonate (APDP), covalently bound to residual aldehyde groups in glu- 
taraldehyde-treated pericardial bioprosthetic tissue, has been shown to inhibit cardiovascu- 
lar calcification in the rat subdermal model. Using 3H-labeled glutaraldehyde (GLUT) at a 
concentration of 0.02 M and 0.14 M r4C-labeled APDP, we assessed the effects of GLUT 
incubation temperature (4” or 25°C) and pH of the GLUT incubation solution (pH 4.0, 7.4, 
or 10.0) on the GLUT incorporation step and subsequent APDP binding (24 hr 25°C) into 
bioprosthetic valve (BPV) tissue (bovine pericardium). Increased incorporation of GLUT 
and APDP occurred at lower GLUT incubation temperature (GLUT, 346.05 2 1.9 nM/mg, 
4°C vs 259.76 + 1.39 nM/mg, 25°C; APDP, 57.56 f  4.43 nM/mg, 4°C vs 36.36 f  0.46 nM/mg, 
mean -C standard error, at 25°C). There also was a greater incorporation of GLUT but not 
APDP at the higher glutaraldehyde pretreatment pH (GLUT, pH 10.0, 213.73 f  73 nM/mg 
vs pH 4, 132.08 f  43 nM/mg; APDP, pH 10.0, 51.41 2 12 nM/mg vs pH 4.0, 49.97 ? 6 
nM/mg). In vivo studies revealed that all groups with treated BPV implanted for 21 days in 
male 3-week-old CD rats demonstrated a loss of both GLUT (12-50%) and APDP (48-64%) 
compared to preimplant content. BPV implant calcification was signiticantly inhibited in all 
groups treated with APDP compared to control Ca” (5.54 f  2.1-9.64 + 1.2 &mg, APDP 
pretreated, vs 93.64 2 11.65 ug/mg, control; P s 0.001) despite the progressive loss of both 
GLUT and APDP with time. It is concluded that preincubation of BPV tissue in GLUT at 
lower temperature (4°C) and higher pH (10.0) enhanced BPV GLUT uptake and subsequent 
APDP covalent binding. In addition, in the rat subdermal model, BPV tissue calcification 
was markedly inhibited by APDP, despite a significant loss of bound drug. 0 1989 Academic 
press, Inc. 
INTRODUCTION 
Calcific degeneration of bioprosthetic heart valves (BPV) fabricated from glu- 
taraldehyde (GLUT)-pretreated porcine aortic valves and bovine pericardium has 
limited their widespread use in the surgical treatment of valvular heart disease (1, 
2). However, because of their central orifice flow characteristics and relative 
nonthrombogenicity compared to mechanical valves, tissue valves would be a 
desirable implant option, particulary in active children and adolescents and 
women of childbearing age (1, 2). Pathologic calcification of the bioprosthetic 
leaflet tissue has been studied experimentally both in orthotopic circulatory im- 
plants in sheep and calves and in subdermal implants in rats, mice, and rabbits. All 
of the experimental explants studied demonstrated pathology and bulk mineral 
accumulation comparable to that noted in clinicopathologic material. 
* To whom reprint requests should be addressed. 
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In previous studies using the rat subdermal model of bioprosthetic tissue cal- 
cification, aminopropanehydroxydiphosphonate (APDP) pretreatment inhibited 
calcification of both porcine aortic valve and bovine pericardial BPV tissue (3,4). 
The APDP was hypothesized in this prior work to covalently bond to residual 
aldehyde functions (noncrosslinked) in the bioprosthetic tissue thereby indicating 
the pathophysiologic importance of the glutaraldehyde-tissue interactions in this 
type of pathologic calcification. However, previous in vitro studies indicated the 
GLUT-APDP bonding to be unstable (6). Hence, the present paper reports the 
results of an extension of this research intended to optimize the use of APDP for 
inhibition of BPV calcification. 
These experiments had as objectives: (i) characterization of the temperature 
and pH dependence of glutaraldehyde uptake by BPV tissue; (ii) assessment of the 
binding characteristics of APDP to BPV tissue after various glutaraldehyde pre- 
treatment conditions; and (iii) assessment of the in vivo anticalcitication efficacy 




Analytic grade glutaraldehyde was obtained as an 8% aqueous solution (Poly- 
science, Warrington, PA). Buffers used for preparation of the glutaraldehyde 
incubation solutions included 0.05 M Hydroxyethylpiperazine-N-ethenesulfonic 
acid Hepes (Sigma Chemical CO., St. Louis, MO) or 0.05 A4 potassium phosphate 
(pH 7.4) in 0.9% NaCl (Fisher Scientific, Fairlawn, NJ) for pH 7.4; 0.05 it4 sodium 
acetate (pH 4.0) in 0.9% NaCl for pH 4.0; and 0.05 M sodium borate (pH 10.0) in 
0.9% NaCl for pH 10.0. [3H]Glutaraldehyde (custom synthesized by New England 
Nuclear, Boston, MA as previously described (4)) was added to 0.2% nonradio- 
labeled glutaraldehyde to produce a solution with a final specific activity of 27.8 
dpm/ti GLUT. i4C-labeled and nonradiolabeled APDP were synthesized by Dr. 
James Benedict (Matrix Medical, Inc., Wheatridge, CO) by reacting B-alanine 
with phosphorus trichloride in a diphosphonate condensation reaction (5) fol- 
lowed by hydrolysis of the cyclic condensation product. APDP was prepared as a 
0.14 M aqueous solution in 0.05 M Hepes (Sigma Chemical Co.) buffer (pH 7.4) 
with 0.9% NaCl (Fisher Scientific), and synthesized 14C-labeled APDP was added 
to the nonradiolabeled APDP solution resulting in a specific activity of 12.5 DPM/ 
ti APDP. 
Parietal pericardium from mature bovines was obtained at slaughter and trans- 
ported to the laboratory on ice. The pericardium was then rinsed free of blood in 
exhaustive volumes of iced sterile saline. Following this, pericardial fat was dis- 
sected from the parietal pericardium for use in the various [3H]GLUT incubation 
protocols (see below). Using a No. 7 cork borer, the pericardium was cut into 
l-cm-diameter pieces and prepared as previously described (4, 6). 
Glutaraldehyde pH Variation 
Incubations of pericardial specimens at pH 4.0 (0.05 M Na acetate, 0.9% NaCl, 
0.2% [3H]glutaraldehyde), pH 7.4 (0.05 M Hepes, 0.9% NaCl, 0.2% 
[3H]glutaraldehyde) and pH 10.0 (0.05 M Na borate, 0.9% NaCl, 0.2% 
13H]glutaraldehyde) were compared. Group numbers correspond to Table I. All 
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TABLE I 
Characteristics of Explanted BPV Preincubated in GLUT and APDP 
21-Day Rat Subdermal Implant 
GLUT Rat 
incubation GLUT Explant Percentage Percentage APDP:GLUT growth 
temperature incubation Ca2 + residual residual %Wt 
Group N C-C) PH Wmg) APDP GLUT Preimplant Explant gain 
I 10 25 4.0 9.64 + 1.25 36 81 0.38 0.17 323 
II 10 25 7.4 7.55 + 0.82 48 50 0.14 0.13 372 
III 9 25 10.0 8.31 2 1.34 52 88 0.24 0.14 362 
IV 10 4 7.4 6.% 2 2.31 
” 
59 0.17 0.12 317 
(VNo APD;; 25 7.4 93.64 2 11.65 40 - - 256 
VI 10 - - 0.58 2 0.02 - - - - - 
(unimplanted) 
Note. Abbreviations used: APDP, aminopropanehydroxydiphosphonate; BPV, bioprosthetic valve 
tissue; Ca”, calcium; GLUT, glutaraldehyde; N, number of specimens; wt, weight. 
incubations were for 7 days. Group I: pH 4.0, T = 25°C; Group II: pH 7.4, T = 
25°C; Group III: pH 10.0, T = 25°C. 
After this initial incubation in [3H]glutaraldehyde, the BPV specimens from 
Groups I-III were exhaustively washed in their specific incubation buffer without 
glutaraldehyde until background levels of ‘H were attained. The specimens were 
then incubated in 0.14 M [14C]APDP (0.05 M Hepes, 0.9% NaCl), at pH 7.4 for 8 
days. 
Samples from each group were then dried to a constant weight in a 100°C oven 
and digested in 1 cc Protosol (New England Nuclear, Billerica, MA) with 100~p,l 
deionized water in a 55°C waterbath for 24 hrs (3, 6). The digests were then 
counted for i4C and 3H radioactivity in a Beckman LS3801 liquid scintillation 
counter (Beckman Instruments, Fullerton, CA). Glutaraldehyde and APDP con- 
tents were calculated from standard curves derived from a series of known glu- 
taraldehyde and APDP concentrations. Glutaraldehyde incorporation and APDP 
incorporation were expressed in nanomoles per milligram dry weight of tissue. 
The remaining specimens in each group were implanted subcutaneously in male 
weanling rats for 21 days (see below). 
Glutaraldehyde Temperature Variation 
Pericardial specimens were prepared as described (above) and samples placed 
in three GLUT solutions. Specific conditions unique to each group are described 
below. The experimental group numbers also correspond to the Roman numerals 
listed in Table I: Group IV, GLUT freshly prepared from stock stored at 4°C. 
Pericardium incubated for 7 days at 4°C then reacted with APDP (see below). 
Group V, GLUT freshly prepared from stock stored at 4°C and not exposed to 
APDP. Pericardium incubated for 7 days at 25°C. 
After 7 days of GLUT incubation, the pericardial pieces were removed from the 
above solutions and washed extensively. Glutaraldehyde-pretreated Group IV 
was placed in 0.14 M [14C]APDP in 0.05 M Hepes, pH 7.4, T = 25°C. Group V 
tissue was placed in 0.05 M Hepes, pH 7.4, T = 25°C. Both groups were incubated 
for 8 days. 
Specimens from each of Groups IV and V were then prepared for digestion in 
Protosol and liquid scintillation counting as described (above), and the remaining 
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specimens from each of the three groups were then implanted subcutaneously in 
young rats (see implant methods below). 
Implantation and Retrieval 
Three-week-old (50-60 g) male Sprague-Dawley rats (CD strain, Charles River 
Laboratories, Burlington, MA) were used. They were fed Lab Chow (Ralston 
Purina, St. Louis, MO). The rats were anesthetized by an intraperitoneal injection 
of ketamine (0.01 mg/g) and each animal received two separate pieces of the 
bovine pericardium prepared as per the above protocols. The pericardial pieces 
were placed in two subcutaneous pouches dissected in the ventral abdominal wall 
which were separated by at least 2 cm. 
After 21 days, the animals were sacrificed by an overdose of sodium pentobar- 
bital and the pericardial specimens retrieved. Blood sampling was performed by 
cardiac puncture at the time of sacrifice and the femurs were removed from 
representative animals from each group for assessment of bone morphology. 
All animals have received humane care in compliance with the “Principles of 
Laboratory Animal Care” formulated by the National Society for Medical Re- 
search and the “Guide for the Care and Use of Laboratory Animals” prepared by 
the National Academy of Sciences and published by National Institutes of Health 
(NIH Publications No. 85-23, revised 1985). The study was approved by the 
Animal Use Committee of the University of Michigan. 
Tissue Calcium Analysis 
Explanted tissue was washed extensively in 0.9% NaCl and deionized water, 
lyophylized, and minced to a tine powder. Calcium levels were determined on 2-3 
mg tissue by atomic absorption spectroscopy (3) after HCl acid hydrolysis. 
Morphologic Analysis 
Following explantation, representative specimens of pericardial tissue were 
immediately placed in Karnovsky’s fixative (7) at pH 7.2. At sacrifice, femurs of 
APDP-treated animals and controls were dissected free of attached muscle and 
fixed in 10% neutral-buffered formalin. Specimens of pericardial tissue and bones 
were prepared for and examined by light microscopy as previously described (4). 
RESULTS 
Glutaraldehyde and subsequent APDP tissue incorporation was enhanced by 
carrying out the BPV glutaraldehyde preincubation step at lower temperature 
(4°C) and higher pH (10.0). Although significant amounts of both GLUT and 
APDP leached out of the tissue after a 21-day in vivo implant (Fig. I), calcification 
of the BPV tissue was significantly inhibited at all levels of APDP and GLUT 
incorporation. Finally, no evidence of diphosphonate toxicity was detected by 
microscopic analysis of the rat femurs (data not shown) or by group comparisons 
of rat growth. 
Effect of Temperature and pH on Uptake (in vitro) 
As shown in Fig. la, a greater amount of glutaraldehyde was incorporated into 
the BPV tissue at the lower incubation temperature (4°C) when compared to the 
samples incubated at room temperature (346.05 2 1.90 niWmg vs 259.76 + 1.39 
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FIG. 1. Dissociation of glutaraldehyde and aminopropanehydroxydiphosphonate (APDP). Glutaral- 
dehyde-pretreated bioprosthetic valve tissue subsequently preincubated in APDP, then implanted 
subcutaneously in weanling male rats (CD, SpragueDawley, 50-60 g) for 21 days. Tissue levels of 
glutaraldehyde and APDP before implant and after explant, showing a decrease after a 21-day implant. 
Group numbers correspond to Table 1. (a) Dissociation of glutaraldehyde: q , incubation T = 4”C, pH 
7.4 (Group IV); + , incubation T = 25”C, pH 7.4 (Group II); 0, incubation T = 25”C, pH 10.0 (Group 
III); W, incubation T = 25”C, pH 4.0 (Group I). (b) Dissociation of APDP: Cl, incubation T = 4°C pH 
7.4 (Group IV); + , incubation T = 25”C, pH 10 (Group III); n , incubation T = 2s”C, pH 4.0 (Group 
I); 0, incubation T = 25”C, pH 7.4 (Group II). 
nM/mg). Paralleling this, a greater amount of APDP was subsequently bound to 
GLUT-pretreated tissue which had been previously incubated at lower tempera- 
ture (57.56 k 4.43 n.M/mg (4”(Z), vs 36.36 k 0.46 nM/mg (25°C)) (Fig. lb). How- 
ever, the ratio of bound APDP:GLUT was 0.16 for the 4°C group vs 0.14 for the 
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25°C group (Table I) indicating the dependency of APDP binding on BPV alde- 
hyde content. 
In general, tissue incorporation of GLUT was pH dependent, with greater 
amounts being incorporated into the BPV tissue at higher pH (Fig. la). Bound 
APDP was 49.97 + 5.68 nM/mg in tissue previously incubated in glutaraldehyde 
at pH 4.0, while it was 51.41 2 12.33 nM/mg in tissue previously incubated in 
glutaraldehyde at pH 10.0 (Fig. lb). Thus, although greater levels of GLUT in- 
corporation are possible at higher pH, the reactivity of the bound GLUT with 
APDP was apparently relatively diminished. 
In Vivo Inhibition of Calcification by APDP 
Tissue calcification was profoundly inhibited in explanted tissue from all ex- 
perimental groups (both temperature and pH) treated with APDP. Explanted tis- 
sue Ca*+ values were slightly higher than those of unimplanted tissue (0.58 + 0.02 
pg/mg) and ranged from 5.54 + 2.08 &mg (T = 25°C pH 7.4) to 9.64 + 1.25 
pg/rng (T = 25°C pH 4.0). Nevertheless, compared to the control value of 93 64 
+ 11.65 kg Ca*+/mg, calcification in all APDP preincubated tissue groups was 
significantly inhibited (Table I, P 6 0.001). 
Light microscopic examination of the implanted tissues confirmed that calcifi- 
cation was virtually nonexistent in the specimens from Groups I to IV (Fig. 2). 
The specimens from Group V demonstrated diffuse and extensive mineralization 
of the central pericardial layer. In addition, the specimens from Group I (pH 4.0, 
T = 25°C) had, despite the lack of calcification, substantial homogenization of the 
connective tissue structure, likely due to autolysis, permitted by the relatively 
incomplete fixation of the acidic glutaraldehyde treatment (Fig. 3). All specimens 
from this group had a disruption of the normally observed discrete, wavy collagen 
bundles of the pericardial structure. Although cells were present between the 
collagen bundles, at the sites of the usual remnant pericardial fibroblasts, the 
exact morphology of these cells present in the specimens from Group I could not 
be determined due to the structural deterioration secondary to insufficient 
crosslinking. 
Glutaraldehyde and APDP Dissociation 
Although significant amounts of both GLUT and APDP leached out of the 
pericardial tissue during the 21-day rat implant (Fig. 1, Table I), relatively larger 
amounts of both GLUT and APDP remained in the explanted tissues which had 
initially been incubated in GLUT at 4°C compared to tissue which had been 
preincubated in GLUT at room temperature (Fig. 1, Table I). APDP:GLUT ratios 
in unimplanted tissue for incubation temperatures of 4°C and 25°C were 0.17 and 
0.14, respectively. After explant, tissue APDP:GLUT ratios for both temperature 
FIG. 2. Photomicrographs of unimplanted bovine pericardium and bovine pericardium from APDP- 
treated and control groups following subdermal implantation for 21 days. (A) Unimplanted bovine 
pericardium demonstrating wavy, dense collagenous structure with interspersed connective tissue 
cells and blood vessels. (B) Pericardium from Group IV (T = 4”C, pH 7.4, APDP treated). No 
mineralization is present. (C) Pericardium from Group V (T = 2X, pH 7.4, no APDP). There is 
severe diffuse calcification. (A) Hematoxylin and eosin. (B, C) von Kossa stain (calcium phosphates 
black). Magnification, all 160x. 
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groups had decreased to 0.12 (Table I). Thus, there was a relatively greater loss 
of APDP compared to the loss of GLUT in explanted BPV tissue. 
Additionally, tissue content of both GLUT and APDP decreased during the 
21-day rat implant regardless of the pH at which the GLUT preincubation took 
place (Fig. 1, Table I). Also, in all experimental groups, there was a relatively 
greater decrease in tissue APDP content compared to GLUT content in the ex- 
planted tissues as indicated by the APDP:GLUT ratios at explant (Table I). Thus, 
both APDPGLUT dissociation and the loss of GLUT occurred, indicating the 
instability of both types of reaction products. 
Lack of Adverse Eflects 
There were no detectable adverse effects caused by covalently bound APDP 
despite apparent in vivo dissociation. Rat growth over the 21-day period ranged 
from 256 to 372% of initial weight and was not affected by a subcutaneous implant 
of APDP-treated pericardial tissue (Table I). Distal femoral epiphyses from the 
animals in all of the experimental groups were without pathologic change com- 
pared to control (data not shown). The microscopic appearance of the distal 
femoral epiphyses from the experimental groups was comparable to that of the 
control. 
DISCUSSION 
Calcification of porcine aortic valve leaflets or bovine pericardium used in BPV 
is dependent, in part, on its pretreatment with glutaraldehyde; however, this 
pretreatment is necessary for tissue crosslinking and sterilization in order to pre- 
vent primary material failure (8, 9). Golomb et al., (8) assessed the effects of 
GLUT incorporation into pericardial tissue and determined that at least 100 ti 
GLUT/mg dry tissue was required for initiation of calcium deposition in the rat 
subdermal model. However, this prior work did not investigate the in vivo disso- 
ciation of glutaraldehyde shown in the present study. 
Results of previous experiments dictated the design of the studies reported in 
this paper. APDP was chosen as the anticalcification agent because BPV prein- 
cubation in ethanehydroxydiphosphonate has been shown to be ineffective for 
calcification prevention (3). The length of incubation in GLUT (7 days) and the 
length of incubation in APDP (8 days) were chosen to correspond to previous 
experimental results (6), demonstrating maximal BPV incorporation of GLUT and 
APDP by 7 and 8 days, respectively. 
Results of the present study have confirmed previous investigations in our 
laboratory demonstrating that the rat subdermal model provides an appropriate in 
vivo system to study the general process of pathologic calcification (3,4,6). Most 
importantly, either glutaraldehyde-pretreated bovine pericardium or porcine aor- 
tic valve leaflets subdermally implanted in rats for 21 days accumulated calcium 
FIG. 3. (A) Photomicrograph of pericardium from Group I (PH 4.0, T = 25”C, APDP treated) 
demonstrating structural homogenization, likely due to incomplete original fixation resulting from 
suboptimal ghnataldehyde incorporation. (B) Adequately fured implant from Group III (PH 10.0, T = 
2X, APDP treated) for comparison. In (A), note the lack of the normal discrete, wavy collagen 
bundles which are present in (B). Cells are present between the collagen bundles, but these cells could 
be remnant from the original pericardial tissue or intlammatory cells of the rat, in which this tissue was 
implanted. Hematoxylin and eosin. Original magnification 150x, insets 375~. 
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levels comparable to that measured in clinical specimens explanted for clinical 
failure after 36 to 156 months (18). Additionally, histologic examination of BPV 
explanted from rat subdermal implants demonstrated the same pathology as that 
seen in clinical explants (l-3). Interestingly, BPV tissue not pretreated with 
GLUT did not undergo calcification in this rat subdermal model, but merely 
underwent necrosis, thus emphasizing the importance of GLUT in this type of 
calcification. The bonding of an anticalcification agent such as APDP to BPV- 
GLUT residues offered a direct means of examining the importance of non- 
crosslinked GLUT to the pathophysiology of BPV calcification. 
The most important result of the present paper was the demonstration of the 
instability of the BPV tissue-glutaraldehyde bond during a 21-day in viva expo- 
sure. This loss of glutaraldehyde tissue crosslinks implies the possibility of ma- 
terial instability over time, which may also enhance the calcification process 
and/or facilitate material-related BPV failure in the circulation. Moreover, the 
BPV GLUT-APDP bond was also unstable in viva. 
Mechanisms for glutaraldehyde binding to bioprosthetic tissue are complex and 
incompletely understood. Initial pathologic calcification of BPV implants is local- 
ized primarily intracellularly within tibroblasts and endothelial cells rendered non- 
viable by the glutaraldehyde pretreatment (1, 2). Subsequent calcium deposition 
involves structural proteins such as collagen (1, 2). Glutaraldehyde reacts prima- 
rily with free amino groups of proteins in the tissue (IO). In the case of collagenous 
tissue such as pericardium, glutaraldehyde binding occurs almost entirely with the 
E amino groups of lysine and hydroxylysine residues of the collagen molecule (11). 
Bowes and Cater have shown that approximately 4 to 5 moles of glutaraldehyde 
are taken up per lysine residue (11). However, not all of this is firmly bound, as 
elemental analysis of reaction products of glutaraldehyde-treated collagen sug- 
gests a ratio of three glutaraldehyde residues per lysine residue (11). Thus, these 
previous in vitro data may explain, in part, the in vivo loss of bound glutaralde- 
hyde noted in the present study. 
The present results also demonstrated that the glutaraldehyde-APDP bond was 
unstable over time in vivo. We hypothesized that the nature of this bond is a Schiff 
base, formed by the reaction of the amino terminus of APDP with a residual 
aldehyde group of glutaraldehyde (11, 12). As Schiff bases are relatively unstable 
at neutral pHs, they may revert to the free amine and aldehyde upon an increase 
in temperature or a decrease in pH (12). In order to stabilize these Schitf bases, 
we theorized that conversion to secondary amines by reduction using a compound 
such as NaBH, as a hydrogen donor would occur. 
In a previous in vitro study, we treated BPV tissue, preincubated in glutaral- 
dehyde and APDP, with NaBH,. Results showed that a greater amount of APDP 
was incorporated in the BPV tissue in the NaBH,-treated group than in the control 
at all time points (1 week, 3 months, 6 months) and at pH 4.0 as well as pH 7.4 (6, 
13). This suggested that NaBH, reduction may play a role in stabilizing the glu- 
taraldehyde-APDP bond. Although in vivo studies have not yet been done, our in 
vitro results indicated that reduction of the GLUT-APDP bond by NaBH, may be 
an effective preincubation strategy for tissue implants. 
Results of the present study also indicated that the higher the pH and the lower 
the temperature of the glutaraldehyde incubation solution, the greater the amount 
of glutaraldehyde bound to BPV tissue. These findings may be due to the greater 
availability of collagen binding sites in the presence of the basic form of the lysine 
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and hydroxylysine residues, as well as the absence of glutaraldehyde polymer- 
ization at lower temperature. The data reported here also indicated that although 
more glutaraldehyde was incorporated into BPV tissue when preincubated at pH 
10.0, there was not a concomitant increase in the amount of APDP bound. This 
may be due to an increased amount of glutaraldehyde autopolymerization at 
higher pH. Rasmussen and Albrechtsen have shown that the higher the pH, the 
greater the degree of autopolymerization at the same temperature (14), and this is 
likely the reason for the lack of increased binding of APDP in spite of higher levels 
of BPV glutaraldehyde. It is possible that high molecular weight polyglutaralde- 
hyde may provide more steric hindrance or perhaps fewer reactive aldehyde 
groups and thus prevent some APDP-GLUT binding which would otherwise have 
occurred with a reaction involving monomeric glutaraldehyde. Also, at lower pH, 
greater amounts of APDP would be present in the acid form, and its amino ter- 
minus would thus be an ammonium residue which would not readily react with 
residual aldehyde groups. 
Previously, we have shown that preimplant APDP tissue levels of 30 ti/mg or 
greater profoundly inhibited BPV tissue calcification in the rat subdermal model 
(6, 13). In the present study, all preimplant APDP tissue levels were found to be 
at least 30 nM/mg. At explant less than half remained but calcification was still 
inhibited. With this result in mind, a feasible approach to prolonged inhibition of 
calcification may be the combined techniques of tissue preincubation in APDP 
with subsequent implantation of a controlled release matrix which would replen- 
ish tissue APDP as it leached out over time. In our laboratory, we have investi- 
gated such drug delivery systems, and the results of these studies (15-17) suggest 
that this combined approach of preincubation and sustained release drug delivery 
may be advantageous. 
CONCLUSION 
The results of these experiments have shown that preincubation of glutaralde- 
hyde-treated BPV in APDP effectively inhibited BPV calcification in the 21-day 
rat subdermal model. BPV tissue uptake of GLUT was enhanced by tissue incu- 
bation at lower temperature (4°C) and higher pH (10.0). However, reactivity of the 
bound GLUT with APDP was relatively diminished at higher pH. After a 21-day 
rat subdermal implant, calcification in all APDP pretreatment groups (temperature 
and pH) was significantly inhibited. Importantly, a significant amount of both 
APDP and GLUT leached out of the BPV tissue during the 21-day implant in all 
experimental groups, suggesting that sustained release APDP delivery may be 
necessary for long-term prevention of BPV calcification. 
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